Private company

Miromatrix Medical Inc.

American biological products company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives. Our proprietary technology is a scalable platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells.”38 It is headquartered in Eden Prairie, Minnesota.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersEden Prairie, Minnesota1
  • Incorporated inDE2
  • Business address6455 Flying Cloud Drive, Suite 107, Eden Prairie, Mn 553442
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

47.6%Gross margin3
-3184.6%Operating margin3
-3142.2%Net margin3
2783.5%Revenue growth, 20223
-114.8%Return on equity3
0.01×Debt to equity3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue2¢$500.0K
  • Research and development67¢$18.3M
  • Selling, general and admin32¢$8.7M

Out of $953.5K in revenue.3 The company lost money this year.

Financial statements

Revenue43$953.5K in 2022+1949% since 2020
0$250.0K$500.0K$750.0K$1.0M2020: $46.5K$46.5K20202021: $33.1K$33.1K2021−29%2022: $953.5K$953.5K2022+2784%
Gross profit43$453.5K in 2022
-$500.0K-$250.0K0$250.0K$500.0K2020: -$453.5K-$453.5K20202021: -$466.9K-$466.9K2021+3%2022: $453.5K$453.5K2022
Operating income43-$30.4M in 2022+196% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$10.3M-$10.3M20202021: -$17.0M-$17.0M2021+65%2022: -$30.4M-$30.4M2022+79%
Net income43-$30.0M in 2022+191% since 2020
-$30.0M-$20.0M-$10.0M02020: -$10.3M-$10.3M20202021: -$14.7M-$14.7M2021+42%2022: -$30.0M-$30.0M2022+104%
Fiscal year2019202020212022
Revenue$46.5K4$33.1K3$953.5K3
Cost of revenue$500.0K4$500.0K3$500.0K3
Gross profit-$453.5K4-$466.9K3$453.5K3
Research and development$7.3M4$10.8M3$18.3M3
Selling, general and admin$2.1M4$4.6M3$8.7M3
Operating expenses$16.5M3$30.8M3
Operating income-$10.3M4-$17.0M3-$30.4M3
Income tax$04$03$03
Net income-$10.3M4-$14.7M3-$30.0M3
Earnings per share-$4.764-$1.283-$1.453
Earnings per share (diluted)-$4.764-$1.283-$1.453
Shares (weighted, basic)11.5M shares320.7M shares3
Shares (weighted, diluted)11.5M shares320.7M shares3

Compare Miromatrix Medical Inc. with another company

Corporate structure

Miromatrix Medical Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Miromatrix Medical Inc.

  • DaVita Filed SC 13G/A on Miromatrix Medical Inc., latest Feb 14, 2024 (2 filings since Feb 11, 2022)
  • Laurence W. Lytton Filed SC 13G/A on Miromatrix Medical Inc., latest Feb 14, 2024 (2 filings since May 11, 2023)
  • Neil Gagnon Filed SC 13G/A on Miromatrix Medical Inc., latest Dec 12, 2023 (3 filings since Feb 16, 2022)
  • First Light Asset Management, LLC Filed SC 13G on Miromatrix Medical Inc., latest Dec 7, 2023
  • Miromatrix Medical Inc. Eden Prairie, Minnesota

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Miromatrix Medical Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$7.4M3 Dec 31, 2022$6.5M3 Dec 31, 2021+14.4%
Accumulated depreciation$1.8M3 Dec 31, 2022$868.8K3 Dec 31, 2021+112.6%
Property and equipment, net$5.5M3 Dec 31, 2022$5.6M3 Dec 31, 2021−0.8%
Finance-lease assets$81.3K3 Dec 31, 2022
Operating-lease assets (leased space)$1.7M3 Dec 31, 2022

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.2M3 Dec 31, 2022$52.8M3 Dec 31, 2021−90.1%
Debt securities held to maturity$20.0M3 Dec 31, 2022

Leadership

Who has led Miromatrix Medical Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jeffrey James Ross2021–2023

Chief financial officer

  1. Brian Niebur2021–2022
  2. James Michael Douglas2022–2023
2025
Board members and other officers (9)

Timeline

  1. Dec 18, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights20
  2. Nov 14, 20238-K Results of operations21
  3. Oct 30, 20238-K Entered a material agreement; Regulation FD disclosure22
  4. Aug 14, 20238-K Results of operations23
  5. Jun 2, 20238-K Shareholder vote24
  6. Jun 1, 20238-K Executive or director change; Regulation FD disclosure25
  7. May 11, 20238-K Results of operations26
  8. Mar 31, 20238-K Results of operations27
  9. Mar 8, 20238-K Entered a material agreement; Results of operations; Regulation FD disclosure28
  10. Feb 1, 20238-K Regulation FD disclosure29
  11. Dec 14, 20228-K Regulation FD disclosure; Other events30
  12. Nov 14, 20228-K Results of operations31
  13. Jun 23, 2021New chief executive Jeffrey James Ross becomes CEO8

Calendar

When it reported results

  1. Nov 14, 2023Reported quarterly or annual results21
  2. Aug 14, 2023Reported quarterly or annual results23
  3. May 11, 2023Reported quarterly or annual results26
  4. Mar 31, 2023Reported quarterly or annual results27
  5. Mar 8, 2023Reported quarterly or annual results28
  6. Nov 14, 2022Reported quarterly or annual results31
  7. Aug 15, 2022Reported quarterly or annual results32
  8. May 16, 2022Reported quarterly or annual results33

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

115 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 22 major events, 49 insider forms, 8 large holders, 27 other. The latest 20:

  1. Feb 14, 2024SC 13G/A EDGAR
  2. Feb 14, 2024SC 13G/A EDGAR
  3. Dec 26, 202315-12G EDGAR
  4. Dec 18, 20238-K EDGAR
  5. Dec 15, 2023EFFECT EDGAR
  6. Dec 14, 20233 OWNERSHIP DOCUMENT EDGAR
  7. Dec 13, 20234 EDGAR
  8. Dec 13, 20234 EDGAR
  9. Dec 13, 20234 EDGAR
  10. Dec 13, 20234 EDGAR
  11. Dec 13, 20234 EDGAR
  12. Dec 13, 20234 EDGAR
  13. Dec 13, 20234 EDGAR
  14. Dec 13, 2023POS AM EDGAR
  15. Dec 13, 2023S-8 POS EDGAR
  16. Dec 13, 2023S-8 POS EDGAR
  17. Dec 13, 2023SC 14D9/A EDGAR
  18. Dec 12, 2023CORRESP EDGAR
  19. Dec 12, 2023SC 14D9/A EDGAR
  20. Dec 12, 2023SC 13G/A EDGAR

The 115 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 10, 2023Douglas James MichaelCHIEF FINANCIAL OFFICERBuy31,250$1.60$50.0KForm 4
Mar 10, 2023Ross Jeffrey JamesCHIEF EXECUTIVE OFFICERBuy31,250$1.60$50.0KForm 4
Mar 10, 2023Barry John JosephVICE PRESIDENT OF R&DBuy6,250$1.60$10.0KForm 4
Mar 10, 2023BUCKMAN PAULDirectorBuy31,250$1.60$50.0KForm 4
Mar 10, 2023Maag PeterDirectorBuy31,250$1.60$50.0KForm 4
Mar 10, 2023ERB JOHN LDirectorBuy31,250$1.60$50.0KForm 4
Mar 10, 2023Burke William P. Mr.DirectorBuy31,250$1.60$50.0KForm 4
Mar 10, 2023Heine Lisa WippermanDirectorBuy31,250$1.60$50.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • DaVitaSC 13G/A, 2 filings Feb 11, 2022 to Feb 14, 202434
  • Laurence W. LyttonSC 13G/A, 2 filings May 11, 2023 to Feb 14, 202435
  • Neil GagnonSC 13G/A, 3 filings Feb 16, 2022 to Dec 12, 202336
  • First Light Asset Management, LLCSC 13G, 1 filing Dec 7, 202337

SEC filer profile

How Miromatrix Medical Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMiromatrix Medical Inc.1
  • CIK0001527096
  • Employer ID (EIN)27-12857821
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address6455 Flying Cloud Drive, Suite 107, Eden Prairie, MN 553441
  • Phone(612)202-70261
  • Shares outstanding27,419,228 as of Nov 9, 20237
  • Public float$73.5M as of Jun 30, 20223
  • On EDGAR sinceDec 2, 20111
  • Filings192 in all: 4 (56), 8-K (26), 3 (15), D/A (11), CORRESP (9), 10-Q (8), UPLOAD (8), SC 13G (5)1
    All 38 form types

    S-1/A (4), SC 13G/A (4), SC 14D9/A (4), 424B5 (3), D (3), EFFECT (3), SC TO-C (3), SC TO-T/A (3), 10-K (2), DEF 14A (2), DRSLTR (2), S-8 (2), S-8 POS (2), 15-12G (1), 25-NSE (1), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), DEFA14A (1), DRS (1), DRS/A (1), POS AM (1), S-1 (1), S-1MEF (1), S-3 (1), SC 13D (1), SC 14D9 (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Quarterly report (10-Q) Nov 14, 2023
    Proxy statement (DEF 14A) Apr 18, 2023
    Latest 8-K (8-K) Dec 18, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38